A Single Case Study on COVID-19 with Ayurvedic Management

Ghosh Rajdeep¹, Sarkar Joy², Ghosh Debasish³*

¹Internal Medicine, GSL Medical College and General Hospital, NH 16, Lakshmi Puram, Rajahmundry, Andhra Pradesh, India; ²Department of Botany, Dinabandhu Andrews College, 54 Raja S.C. Mallick Road, Kolkata, West Bengal, India; ³Kayachikitsa (Internal Medicine), Vishwanath Ayurved Mahavidyalaya and Hospital, 94, Grey Street, Kolkata, West Bengal, India.

INTRODUCTION

At the beginning of 2020, a new novel SARS-CoV-2 viral disease with flu or influenza-like symptoms has introduced a global pandemic causing a mammoth human loss. The epicentre of the disease is believed to be the Wuhan province of China.¹ The zoonotic transmission of the contagious disease quickly transformed its course into a human-to-human transmission, resulting in the rapid spread of the disease in a very short period.² On 30th January 2020, the declaration of a public health emergency and temporary recommendations by the Director-General of the World Health Organization (WHO) emerged as a global concern on the pandemic issue.³,⁴ There were so many medicinal plants in Ayurveda that have antiviral activities. Some of them if proven their efficacy for controlling the SARS-CoV2 virus that will be a summum bonum for the sufferings humanity.

Ayurveda means not only the knowledge of life but also it describes the way of life. It originated in India more than five thousand years back. The description of the medicinal plants is persisting since the period of Vedas and was later found in the several Nighantus of Ayurveda.⁵ Many herbs in Ayurveda have antibacterial, antifungal, and antiviral properties that have been revalidated and confirmed by modern scientists in various studies. In day-to-day practise or home remedies, we used these plants from generation after generation for the management of several viral diseases, such as for the management of viral fever or common cold.
There has been a phenomenal increase in the demand for specialized therapies of Ayurveda. Many of the treatment failure patients of the conventional system of medicine are coming to be treated at the different institutes of Ayurveda with a hope of recovery in this ancient system of medicine. The present single-case study will throw light on the ayurvedic management of clinical conditions of a corona positive patient.

**Case Presentation**

**Patient information**
A 45 years patient is a Staff Nurse in the Government hospital of Kolkata, West Bengal, India. She is well built, with a height of 153 cm and weighing 65 kg.

**Present medical history**
The patient on the first day of falling ill with a runny nose, fever, sore throat, mild breathing difficulty contacted an Ayurvedic physician of her hospital and started on ayurvedic medication for her complaints. She self-quarantined on the suspicion of the possibility of a COVID-19 infection.

**Past medical history**
She had several histories of certain diseases and complications. She had a long history of COPD (Chronic Obstructive Pulmonary Disorder), Diabetes mellitus Type-2 and Rheumatoid Arthritis. She had taken Hydroxychloroquine 300–1 Tab OD, Sulfasalazine 500–1 Tab OD, Deflazacort Tab 6 mg (corticosteroid) (not taken regularly) for Rheumatoid Arthritis. She had taken Montelukast Levocetirizine combination twice daily, Levosalbutamol inhaler twice daily and Formoterol fumarate and Budesonide inhaler (used in severe breathing problems) in COPD and for Diabetes mellitus Type-2, she had used Metformin 500 mg twice daily. Now, she has shifted to ayurvedic treatment for Rheumatoid Arthritis for the last 2 years. From 2019, she had not taken any medicine other than ayurvedic medication for Rheumatoid Arthritis.

**Pathophysiology**
In his present illness, she was presenting the symptoms like kwara (fever), swasa (breathing difficulty) and kasa(coughing). These three main symptoms of COVID-19 belong to Abhyantararogamargais one of the three rogamargas or “pathways of disease” as described in AstangaHridayam. Pranavahasrotodushti (vimana sthana 5/7) is found in this disease, as there is severe respiratory distress associated with other symptoms, causing death sometimes.6

Based on that concept, COVID 19 can be correlated with Aguntujasannipatajwara, which is of Vata–Kapha predominance (chikitsasthana, 3/92, 3/128-129). This kwara is classified as being agantu (external) caused by bhoota Abhisangha (chikitsasthana 3/111, 3/114), which aggravates all three doshas. As all three doshas are aggravated, it may also be termed as sannipata.6

**Diagnosis**
In this disease, the diagnosis was first done based on her symptoms, signs and season. But the final diagnosis was done by RT-PCR test for SARS-CoV-2.

**Etiology**
COVID–19 is a highly infectious disease, caused by SARS-CoV2. According to Susruta Samhita: NidanaSthana, 5th chapter:
The infectious diseases can be transmitted from one to another through sneezing, coughing, touching, eating with the infected one in the same dish, lying in the same bed and contact with clothes, ornaments and cosmetics.

**Therapeutic intervention**
Medicines, diet, and regimen are the three fundamentals of therapeutic intervention. The patient had been self-quarantined from the first day of fever. Complete medication consists of two stages of her condition namely fever and convalescence. Details of all the date wise symptoms, Test Results, treatment, diet and regimen are given in a tabular form. (Table 1).

**DISCUSSION**
This is a case study, based on the management of COVID-19 daily. The role of Ayurvedic herbal and herbs-mineral drugs in the treatment and prevention of COVID-19 has been well established in this study.

**Limitation**
This is a single case study but it may invite a larger sample of studies before we will develop a standard protocol for the treatment of COVID-19. The treatment was done on telephonic discussion and video conferencing. There was no chance to examine the patient physically.

**Strengths**
It was observed that the patient condition did not deteriorate with the ayurvedic management. Even all symptoms of the patient were subsided gradually one by one. The COVID-19 diseases may resemble the vatakafaja and sannipataja kwara. Mrityunjay Ras, MahaSudersan, SanjivaaniVati are commonly used in Ayurveda for the treatment of vataja and sannipataja kwara. So, these medicines worked nicely. Guduchi (Tinospora cordifolia) and bhuinamla (Pylanthusniruri) have been proved for their immunomodulatory and antiviral activities respectively. So, these herbs were used for the treatment of COVID-19 in this study. Anu taila and Triphalachurna were used for the regaining of taste and
smell. *Aswagandha* and *Amlaki* contain natural Zinc and Vitamin C along with many other beneficial components were used for the general weakness of the patient. The practice of pranayama for 30 minutes daily was advised for maintaining $O_2$ saturation level as normal.

**Active principles and mode of action of used medicinal plants**
The active principles and probable mode of action of medicinal plants used in this management of the patient of COVID-19 are documented in a tabular form (Table 2).

### Table 1: Detailed course of the disease

| Date       | Symptoms                                      | Test/Result                                      | Treatment                                                                 | Diet                                      | Regimen                                          |
|------------|-----------------------------------------------|--------------------------------------------------|---------------------------------------------------------------------------|-------------------------------------------|--------------------------------------------------|
| 24.07.2020 | 1. Fever 101˚ F 2. Sore throat                | NA                                               | 1. Tab *Mrityunjayras*  
2. Tab *Sanjivani*  
3. Tab *Mahasudarasanvati*  
Above all of 1 Tab each twice daily after breakfast and tiffin.  
2. *Guduchichurna* 1 Tsf + *Bhuinamla* 1/2 Tsf one dose before lunch and dinner.  
3. *Ayushkwath* 1/2 Tsf with a cup of lukewarm water in the morning and evening. | Non-spicy nutritious diet was advised to take.  
1. Pranayam for 30 minutes in the morning  
2. Stop sleeping during the day (Divaswapna) and avoid staying up at night (Ratrijagarana) | 1. Same as above  
2. *Sringadhichurna* 1 TsF BD with lukewarm water  
3. *Sashkutharasi* Tab BD |
| 25.07.2020 | 1. Fever 102˚ F 2. Sore throat 3. Mild coughing 4. Mild breathing difficulty | Home test for COVID–19.  
Nasopharyngeal Test: Real-Time RT-PCR test from Dr. Lal Path Labs (Kolkata Reference Lab) Kolkata. Result: positive for SARS-CoV-2. | 1. Same as above  
2. *Sringadhichurna* 1 TsF BD with lukewarm water  
3. *Sashkutharasi* Tab BD | 1. Same all medicines continued; Additional treatment for loss of smell: *Anu tailamnasya* two drops in each nostril, twice daily |
| 26.07.2020 to 03.08.2020 | 1. Fever and sore throat subsided 2. Occasional Coughing and mild breathing difficulty persist. 3. Loss of smell | NA                                               | Same all medicines continued; Additional treatment for loss of smell: *Anu tailamnasya* two drops in each nostril, twice daily | Same as above except medication of 1 and 2 as of 24th July 2020 |
| 04.08.2020 | Same                                          | NA                                               | Same as above except medication of 1 and 2 as of 24th July 2020          | 1. *Aswagandhachurna* 3 gm BD with a cup of milk.  
2. Rinse mouth with *Triphalachurna* with lukewarm water for 10 minutes twice daily | 1. Same as above except medication of 1 and 2 as of 24th July 2020 |
| 05.08.2020 to 11.08.2020 | All symptoms are subsided except the loss of taste and general weakness. | Advised RT-PCR test for SARS-CoV-2 on 11.08.2020 | 1. *Aswagandhachurna* 3 gm BD with a cup of milk.  
2. Rinse mouth with *Triphalachurna* with lukewarm water for 10 minutes twice daily | 1. Same as above except medication of 1 and 2 as of 24th July 2020 |
| 12.08.2020 & 13.08.2020 | Taste and smell were felt as earlier but general weakness persisting. | RT-PCR test for SARS-CoV-2 was done on 12.08.2020 and detected negative on 13.08.2020 | 1. *Aswagandhachurna* 3 gm BD with a cup of lukewarm milk  
2. *Amlakichurna* 3 gm BD advised to be continued for one month. | 1. Same as above except medication of 1 and 2 as of 24th July 2020 |
Table 2: Chemical structures, active principles and mode of action of the medicinal plants used in the treatment

| Sl. No. | Name of the Medicinal Plant | Parts Used | Active Principle | Possible Structure | PubChem Structure Reference | Mode of Action | Reference |
|---------|------------------------------|------------|------------------|-------------------|-----------------------------|----------------|----------|
| 1       | *Tinospora cordifolia* (Willd.) Miers. | Stem | Cordifolide A | [Chemical Structure](CID_102451916) | These are the inhibitors of RNA dependent RNA polymerase of Severe Acute Respiratory Syndrome Coronavirus-2. |
| 2       | *Withania somnifera* (L.) Dunal. | Root | Withaferin A | [Chemical Structure](CID_265237) | It can regulate the consequence of COVID-19 and modulate the Th1/Th2 dependent immunity in the host. Immunity is also given by increasing the IFN-γ. |
| 3       | *Embelica officinalis* Gaertn. | Fruit | Pentagalloyl glucose | [Chemical Structure](CID_65238) | It may be able to prevent the replication of the influenza A virus. It also can increase immunity as well. |
| 4       | *Terminalia chebula* Retz. | Fruit | a) Gallic Acid | [Chemical Structure](CID_370) | It is known for its antiviral properties, and it boosts immunity by increasing neutrophil activity or T-cell and B-cell proliferation and the level of IL-2, IL-10, and TNF-α. |
|         |                              |           | b) Ellagic Acid | [Chemical Structure](CID_528855) |                             |
| 5       | *Phyllanthus amarus* Schumach. & Thonn. | Whole Plant | Geraniin | [Chemical Structure](CID_3001497) | It inhibits the activity of pathogen proteins. |
Rajdeep et al: A single case study on COVID-19 with ayurvedic management

| Sl. No. | Name of the Medicinal Plant | Parts Used | Active Principle | Possible Structure | PubChem Structure | Mode of Action | Reference |
|---------|-----------------------------|------------|------------------|--------------------|------------------|---------------|-----------|
| 6       | Terminalia bellirica (Gaertn.) Roxb. | Fruit | a) Gallic Acid  
          b) Ellagic Acid | CID_370  
CID_528855 | It is known for its antiviral properties, and it boosts immunity by increasing neutrophil activity or T-cell and B-cell proliferation. | 14,15 |

**Patient’s perspective informed consent**

“Iam a staff nurse GR-2 under Health and Family Welfare Department, Government of West Bengal. I am a chronic patient of Rheumatoid arthritis and suffering from mild Asthma. Previously, I suffered from Pancreatitis and so I had gone through many surgeries.

My husband (he has no medical problems) developed a fever on 24th July 2020 and I had consulted with Dr D. Ghosh, Superintendent of Viswanath Ayurved Mahavidyalaya and Hospital, Kolkata, India where I have been transferred on February 20. He advised me for home isolation and also for the test of COVID-19 for all of my family members. On 25.07.2020, I and my husband tested positive at Dr Lal Path Lab.

I tried for the COVID test from 21.07.2020 at home because my husband was suffering from a high fever and was very weak and I have a kid also but I was unable to do so till 23/07/2020 then Dr Ghosh helped me with that and finally the test was done on 24/7/2020. We were in home isolation and took treatment from Ayurveda under the advice of Dr Ghosh.

Although I am very new to this stream of treatment (Ayurveda) Dr Ghosh helped me with this Ayurveda and treated us symptomatically. I arranged O₂ inhalation at home because of my asthma. Both of us got various symptoms of COVID and due to my co-morbid diseases, I was very much afraid of the worst. But Dr Ghosh gave me mental assurance and enough courage to me along with this Ayurveda. Gradually, we were being asymptomatic and my asthma and other complications were vanishing. I was taken aback that Ayurveda can do this! To be honest, we had suffered too much but feel no need for hospitalization because of Dr Ghosh’s determination and help for every minor problem. At last, we became cured and tested negative. We both are amazed by the phonic treatment according to our symptoms provided by Dr D. Ghosh. I feel proud as a government staff under health and family welfare for the treatment of Ayurveda. Now, I am trying to convert my treatments from Allopath to Ayurveda, the ancient treatment therapy of India. At last, I again want to thank Dr D. Ghosh for not only his treatment but also for his behaviour and supporting attitude.”

**Declaration of patient consent**

The authors certify that they have obtained all appropriate patient consent forms. In the form, the patient has given her consent for her clinical information to be reported in the journal. The patient understands that her name and initials will not be published and due efforts will be made to conceal her identity, but anonymity cannot be guaranteed.

**CONCLUSION**

This is a single case study, but this study may give a ray of hope to prepare a standard protocol for the treatment of highly infective COVID-19 disease. But further extensive studies are needed in a larger sample size to develop the standard protocol of Ayurveda for the treatment of the
disease. Future researcher may carry out their research on the ayurvedic line-up treatment based on this clinical case study.

**ACKNOWLEDGEMENTS**

The authors acknowledge the immense help received from the scholars whose articles are cited and included in references of this manuscript. The authors are also grateful to authors/editors/publishers of all those articles, journals and books from where the literature for this article has been reviewed and discussed.

**Statement of Ethics**

**Ethics approval**

This is not a clinical trial and the medicines, used in this treatment are using years together in Ayurveda for treatment of fever of viral or another origin, not new or used for the first time. However, these medicines are evidence-based and this use in treatment needs no ethical clearance according to the research protocol of WHO.

**Study approval statement**

Not Applicable

**Ethical Review Board**

Not Applicable.

**Consent for Publication of case**

Written informed consent was obtained from the patient for publication of this case report and any accompanying images. Written consent of the patient is also submitted to the Journal Site as Supplementary data.

**Conflict of Interest Statement**

The authors have no conflicts of interest to declare.

**Funding Sources**

We don’t have any funding support from any organizational or institutional level.

**Author Contributions**

Conceptualization: [Debasish Ghosh], [Rajdeep Ghosh]; Methodology: [Debasish Ghosh], [Rajdeep Ghosh]; Formal analysis and investigation: [Debasish Ghosh], [Rajdeep Ghosh]; Writing—original draft preparation: [Rajdeep Ghosh], [Debasish Ghosh]; Writing—review and editing: [Joy Sarkar]; Funding acquisition: [N/A]; Resources: [N/A]; Supervision: [Joy Sarkar], [Debasish Ghosh]

**Data Availability Statement**

All the available data are given in supplementary files.

**REFERENCES**

1. Paraskevis D, Kostaki EG, Magiorkinis G, Panayiotakopoulos G, Sourvinos G, Tsiodras S. Full-genome evolutionary analysis of the novel coronavirus (2019-nCoV) rejects the hypothesis of emergence as a result of a recent recombination event. *Infect Genet Evol.* 2020;79:104212. doi:10.1016/j.ijge.2020.104212

2. Ghosh R, Palbag S, Ghosh D. In-silico screening of active molecules from medicinal plant resources for controlling SARS-CoV-2 infection. *J. Ayu. Her. Med.* 2020;6(3):149-153. doi:10.31254/jahm.2020.6310

3. WHO. *World Health Organization Statement on the Second Meeting of the International Health Regulations (2005) Emergency Committee Regarding the Outbreak of Novel Coronavirus (2019-nCoV).*; 2020.

4. SankariNiveditha A, Geetha R v., Arivarasu L. Will alternative medicine help us to fight against COVID-19. *Int. J. Curr. Res. Rev.* 2020;12(21 Special Issue):112-116. doi:10.31782/IJCCR.2020.SP47

5. Preethi G, Premavathy D. A review on exploring the Siddha and ayurvedic medicines for covid-19 infection. *Int. J. Curr. Res. Rev.* 2020;12(21 Special Issue):10-13. doi:10.31782/IJCCR.2020.SP48

6. Girija PLT, Sivan N. Ayurvedic treatment of COVID-19/ SARS-CoV-2: A case report. *J. Ayu. Int. Med.* 2020;(xxxx):2-6. doi:10.1016/j.jaim.2020.06.001

7. Koulgi S, Jani V, MallikarjunachariUppuladinne VN, Sonavane U, Joshi R. Natural plant products as potential inhibitors of RNA dependent RNA polymerase of Severe Acute Respiratory Syndrome Coronavirus-2. *PLoS ONE.* 2021;16(5 May):1-18. doi:10.1371/journal.pone.0251801

8. Patwardhan B, Chavan-Gautam P, Gautam M, et al. Ayurveda rasayana in prophylaxis of COVID-19. *Comm.Curr. Sci.* 2020;118(8):1158-1160. doi:10.7326/M20

9. Bhattacharya A, Ghosal S, Bhattacharya SK. Antioxidant activity of tannoid principles of *Emblica officinalis* (amla) in chronic stress induced changes in rat brain. *Indian J. Exp. Biol.* 2000;38(9):877-880.

10. Saxena M, Saxena J, Nema R, Singh D, Gupta A. Phytochemistry of Medicinal Plants. *J. Pharmacogn. Phytochem.* 2013;1(6):168-182.

11. Shivprasad H, Rana A, Mohan S. Preliminary Immunomodulatory Activities of the Aqueous Extract of *Terminalia chebula.* *Pharm. Biol.* 2006;44(1):32-34. doi:10.1080/13880200500530542

12. Aher V, Wahi A. Immunomodulatory Activity of Alcohol Extract of Terminalia chebula Retz Combretaceae. *Trop. J. Pharm. Res.* 2011;10(5):567. doi:10.4314/tjpr.v10i5.5

13. Hiremath S, Kumar HDV, Nandan M, et al. In silico docking analysis revealed the potential of phytochemicals present in *Phyllanthus amarus* and *Andrographis paniculata*, used in Ayurveda medicine in inhibiting SARS-CoV-2. *3 Biotech.* 2021;11(2):1-18. doi:10.1007/s13387-020-02578-7

14. Deb A, Choudhury G, Barua S, Das B. Pharmacological activities of Baheda (Terminalia bellerica): A review. *J. Pharmacogn. Phytochem.* 2016;5(1):194-197.

15. Gupta A, Kumar R, Kumar S, Pandey AK. *Pharmacological Aspects of Terminalia Bellerica Phytochemistry View Project Clinical Biochemistry and Drug Development View Project.* Lenin Media Private Limited, Delhi, India; 2017.